Skip to main content

Ocular Therapeutix, Inc. (OCUL)

NASDAQ: OCUL · IEX Real-Time Price · USD
10.50
-0.05 (-0.47%)
After-hours:Sep 17, 2021 7:58 PM EDT
10.55
0.23 (2.23%)
At close: Sep 17, 4:00 PM
Market Cap807.95M
Revenue (ttm)32.29M
Net Income (ttm)-102.92M
Shares Out76.32M
EPS (ttm)-1.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,113,049
Open10.36
Previous Close10.32
Day's Range10.12 - 10.59
52-Week Range7.50 - 24.30
Beta2.12
AnalystsBuy
Price Target24.43 (+131.6%)
Est. Earnings DateNov 4, 2021

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an ax...

IndustryPharmaceuticals
IPO DateJul 25, 2014
CEOAntony Mattessich
Employees181
Stock ExchangeNASDAQ
Ticker SymbolOCUL
Full Company Profile

Financial Performance

In 2020, OCUL's revenue was $17.40 million, an increase of 311.71% compared to the previous year's $4.23 million. Losses were -$155.64 million, 80.2% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is 24.43, which is an increase of 131.56% from the latest price.

Price Target
$24.43
(131.56% upside)
Analyst Consensus: Buy

News

Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

4 days ago - Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapie...

1 week ago - Business Wire

This Exciting Biopharma Could Earn You 55% in 12 Months

When patients see more clearly, so too should investors.

3 weeks ago - The Motley Fool

4 Reasons I Just Bought Ocular Therapeutix Stock

This company's drug delivery technology just isn't getting the appreciation it deserves right now.

3 weeks ago - The Motley Fool

Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More

With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.

Other symbols:SDCSQSPVSCOARCTBHVN
1 month ago - 24/7 Wall Street

Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

Ocular Therapeutix (OCUL) Reports Q2 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -25.00% and 0.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.

Other symbols:REGN
1 month ago - Benzinga

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulat...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment o...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

Ocular Therapeutix™ To Report Second Quarter 2021 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

1 month ago - Business Wire

After Plunging 19.8% in 4 Weeks, Here's Why the Trend Might Reverse for Ocular Therapeutix (OCUL)

The heavy selling pressure might have exhausted for Ocular Therapeutix (OCUL) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street an...

1 month ago - Zacks Investment Research

Ocular Therapeutix™ To Present Clinical Data at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) ...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

Ocular Therapeutix™ Announces Second Quarter 2021 Preliminary Net Product Revenue of $11.7 Million

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

1 month ago - Business Wire

3 Top Life Science Stocks to Buy on Sale Right Now

Shares of these overlooked gems could make investors very rich once the rest of the market notices their value.

Other symbols:AMRSRNLX
2 months ago - The Motley Fool

Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dr...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

2 months ago - Business Wire

Ocular Therapeutix™ to Participate at Three Upcoming Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

3 months ago - Business Wire

Implied Volatility Surging for Ocular Therapeutix (OCUL) Stock Options

Investors need to pay close attention to Ocular Therapeutix (OCUL) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

4 months ago - Business Wire

CORRECTING and REPLACING Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Re...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Please replace the release dated April 29, 2021, with the following corrected version due to multiple revisions. The updated release: OCULAR THERAPEUTIX...

4 months ago - Business Wire

Ocular Therapeutix™ Fulfills Post-Marketing Approval Requirements for ReSure® Sealant

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

4 months ago - Business Wire

Ocular Therapeutix™ To Present Pre-Clinical and Clinical Data at the 2021 Association for Research in Vision and Opht...

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapi...

4 months ago - Business Wire

Ocular Therapeutix™ To Report First Quarter 2021 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

4 months ago - Business Wire